Yantai Patronus Biotech Co., Ltd.
12
0
2
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
2 terminated/withdrawn out of 12 trials
0.0%
-86.5% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years
Role: collaborator
A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults
Role: collaborator
Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination
Role: collaborator
Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older
Role: collaborator
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
Role: collaborator
Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above
Role: collaborator
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
Role: collaborator
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002
Role: collaborator
Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above
Role: collaborator
The Phase Ⅱ/Ⅲ Trial of LYB001
Role: lead
Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001
Role: lead
A Phase Ⅰ Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001
Role: lead
All 12 trials loaded